MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention

NCT05305560 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2024-12-31

Study results available
· View outcomes & findings →

Summary

A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis

Conditions

Interventions

DRUG

Ivermectin Tablets

Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.

DRUG

Matching placebo tablets

Daily placebo tablets intake for 28 days

Sponsors & Collaborators

  • Violaine Desort-Hénin, DVM

    collaborator UNKNOWN

  • MedinCell S.A

    lead INDUSTRY

Principal Investigators

  • Anna Kostova, MD · Medical Center Medic Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-25
Primary Completion
2022-09-15
Completion
2022-10-13

Countries

  • Bulgaria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305560 on ClinicalTrials.gov